Alavert Allergy and Sinus
Name: Alavert Allergy and Sinus
- Alavert Allergy and Sinus used to treat
- Alavert Allergy and Sinus is used to treat
- Alavert Allergy and Sinus uses
- Alavert Allergy and Sinus drug
- Alavert Allergy and Sinus adverse effects
- Alavert Allergy and Sinus side effects
- Alavert Allergy and Sinus effects of
- Alavert Allergy and Sinus tablet
- Alavert Allergy and Sinus mg
- Alavert Allergy and Sinus 60 mg
Uses of Alavert Allergy and Sinus
- It is used to treat nose stuffiness.
- It is used to ease allergy signs.
Consumer Information Use and Disclaimer
- If your symptoms or health problems do not get better or if they become worse, call your doctor.
- Do not share your drugs with others and do not take anyone else's drugs.
- Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.
- Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.
- Some drugs may have another patient information leaflet. Check with your pharmacist. If you have any questions about this medicine (Alavert Allergy and Sinus), please talk with your doctor, nurse, pharmacist, or other health care provider.
- If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.
This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine (Alavert Allergy and Sinus). It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine (Alavert Allergy and Sinus).
Review Date: October 4, 2017
What are some other side effects of this drug?
All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:
- Feeling nervous and excitable.
- Not able to sleep.
- Feeling sleepy.
These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.
You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch.
Liver Dose Adjustments
The manufacturer recommends that tablets containing loratadine in fixed combination with pseudoephedrine sulfate generally not be used in patients with hepatic impairment.
1 tablet (5 mg-120 mg) orally once daily
1 tablet (10 mg-240 mg) orally every other day.
Pseudoephedrine is partially removed by hemodialysis, therefore doses should be given following dialysis sessions.
Loratadine / pseudoephedrine Pregnancy Warnings
Loratadine-pseudoephedrine has not been assigned to a pregnancy category by the FDA. Animal studies have failed to reveal evidence of teratogenicity. There are no controlled data in human pregnancy. Loratadine-pseudoephedrine is only recommended for use during pregnancy when benefit outweighs risk.
A case controlled surveillance study reported an elevated relative risk (3.2) of gastroschisis with first-trimester pseudoephedrine use in 76 cases. The relative risk for other drugs was 1.6 for salicylates, 1.7 for acetaminophen, 1.3 for ibuprofen, and 1.5 for phenylpropanolamine (not significant). The authors hypothesized vascular disruption was the etiology of gastroschisis. A second group of 416 infants with heterogenous defects suspected to have a vascular etiology was studied. There was no increased risk associated with the use of salicylates, ibuprofen, pseudoephedrine, phenylpropanolamine, and other decongestants. These data require independent confirmation. In a review of 229,101 deliveries to Michigan Medicaid patients, 940 first-trimester exposures to pseudoephedrine were recorded and 191 exposures any time during pregnancy. A total of 37 birth defects were reported with first trimester exposure (40 expected) and included (observed/expected) 3/9 cardiovascular defects, 2 oral clefts, and 3/2 polydactyly. These researchers reviewed nine cases of abdominal wall defects in the 1980 to 1983 Medicaid data. Seven of the nine cases occurred in 3752 pseudoephedrine exposed pregnancies, providing a relative risk of 1.8. Only one case was a surgically treated abdominal wall defect (written communication, Franz Rosa, MD, Food and Drug Administration, 1994). The Collaborative Perinatal Project monitored 50,282 mother-child pairs. Only 39 first-trimester exposures to pseudoephedrine were recorded, with one birth defect observed. For use any time during pregnancy, 194 exposure were recorded with 3 birth defects observed (3.22 expected). The effect of pseudoephedrine on uterine and fetal blood flow was studied in 12 healthy pregnant women between 26 and 40 weeks gestation. Following a single 60 mg dose of pseudoephedrine, no significant effect was seen on fetal heart rate, uterine blood flow, or fetal aortic blood flow. There are no other data on the use of loratadine during pregnancy.
Loratadine / pseudoephedrine Breastfeeding Warnings
Loratadine concentration in human milk approximate that found in the serum of the mother. Approximately 0.029% of the administered dose is excreted in human milk. Pseudoephedrine is also excreted into human milk. Three mothers given pseudoephedrine demonstrated milk concentrations consistently higher than plasma concentrations. Maximum milk concentrations were reached at 1 to 1.5 hours after dosing. In one woman, the milk:plasma concentration ratio at 1, 3, and 12 hours was 3.3, 3.9, and 2.6. The authors calculated that 1000 mL of breast milk consumed over 24 hours would provide an infant with 0.25 to 0.33 mg of pseudoephedrine or 0.5% to 0.7% of the dose ingested by the mother. There are no reports of adverse effects in infants who were exposed to pseudoephedrine by breast milk. The American Academy of Pediatrics considers pseudoephedrine to be compatible with breast-feeding. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.